Global dyspepsia drugs market projected to grow from USD 9.5 billion to USD 14.7 billion by 2033

From GlobalNewswire: 2024-05-30 21:00:00

The Global Dyspepsia Drugs Market is projected to grow from USD 9.5 Billion in 2023 to USD 14.7 Billion by 2033 with a CAGR of 4.46%. Functional dyspepsia symptoms include gassiness, early satiety, and postprandial fullness. Treatment involves lifestyle changes and medication. Market growth is driven by the increasing prevalence of functional dyspepsia and the rising geriatric population.

The proton pump inhibitors surgery segment is expected to hold the largest market share through the forecast period. Branded medications are anticipated to grow at the fastest CAGR rate. Over-the-counter medications dominate the market, with retail pharmacies holding the largest revenue share. The Asia-Pacific region leads the market, with North America expected to grow rapidly due to rising cases of dyspepsia and investment in healthcare infrastructure.

Key players in the global dyspepsia drugs market include AstraZeneca, Pfizer, Sanofi, Abbott Laboratories, and more. Recent developments include the approval of Acofide in Thailand and the first-to-market launch of Naproxen and Esomeprazole Magnesium Tablets by Dr. Reddy’s Laboratories. The market is segmented by indication, drug type, medication, mode, distribution channel, and region. Market forecasts are available up to 2033.



Read more at GlobalNewswire: Global Dyspepsia Drugs Market Size To Worth Exceed USD 14.7